Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others


Displaying 1 to 10 of 53 Posts . Displaying 10 of Posts . Page of 6 . Go To Page: . Per Page: . . . View All Sort By: .

Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis

Eli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).

Read More

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.

Read More

Updated Disease Classification System Adopted by the World Health Organization

On 25 May 2019, the World Health Assembly officially adopted the eleventh revision of the International Classification of Diseases (ICD-11). The ICD-11 will come into effect on 1 January 2022.

Read More

FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)

Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab)i , for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. Please see full indications and Boxed Warning for HADLIMA™, below.

Read More

Meta-Analysis Shows Patients With Psoriasis at Significantly Elevated Risk for Cancer

In a study presented at the British Association of Dermatologists’ 99th Annual Meeting in Liverpool, United Kingdom, July 2-4, 2019, researchers from the University of Manchester and the Salford Royal National Health Service Foundation Trust reported on an effort to assess evidence on the risk of cancer in patients with psoriasis.

Read More

Now Available: IPC 2019 Biosimilars Education Initiative

Stay up to date on biosimilars in psoriasis and provide the best care for your patients.

Read More

IPC's July 2019 Psoriasis Review newsletter is now available!

Just published - IPC's latest issue of the Psoriasis Review newsletter featuring the Top 5, symposia reports, and more! The IPC Psoriasis Review newsletter provides practicing physicians with an authoritative research review that targets a range of key psoriasis publications most relevant to current clinical practice. The newsletter leverages the collective research and clinical expertise of IPC’s Councilors to identify the most important publications in psoriasis from the past year and provide a concise editorial commentary on the value of these publications.

Read More


ORTHO DERMATOLOGICS ANNOUNCES U.S. LAUNCH OF DUOBRII™ (HALOBETASOL PROPIONATE AND TAZAROTENE) LOTION 0.01%/0.045% FOR PLAQUE PSORIASIS IN ADULTS RALEIGH, N.C., June 25, 2019 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that DUOBRIITM (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, will be available commercially to health care professionals starting this week. Approved by the U.S. Food and Drug...

Read More

Review of international psoriasis guidelines for the treatment of psoriasis: recommendations for topical corticosteroid treatments

Corticosteroid therapy is regarded as first-line therapy for treating mild psoriasis and recalcitrant lesions. Members of the IPC Topical Therapies Working Group reviewed available international topical corticosteroids guidelines in order to understand current information and to identify areas that would benefit from greater practical guidance for dermatologists.

Read More

FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis' Second Anti-TNF Medicine in the United States

Samsung Bioepis expands autoimmune portfolio in the United States with FDA approval of ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL®i (etanercept). INCHEON, Korea – As of April 2019 – Samsung Bioepis Co., Ltd. today announced that the US Food and Drug Administration (FDA) has approved ETICOVO™ (etanercept-ykro), a biosimilar referencing ENBREL® (etanercept), across all eligible indications for the treatment of rheumatoid arthritis, ankylosing...

Read More

The mechanistic model(s) of psoriasis: Autoimmune and/or inflammatory?

Wednesday, September 18, 2019
2:00 pm - 6:00 pm
Bordeaux, france
Register Now

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.

This website uses cookies. Please ensure your cookies are enabled.